Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 24
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Eton Pharmaceuticals Inc
ETON
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$50.00
-0.02
-0.04%
Ult. Agg.: Oct 23, 7:20 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Eton Pharmaceuticals Financials
Eton Pharmaceuticals (ETON) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.
Avi Kapoor
PRO
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of $0.07 per share from
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
